Company news
Valion Bio, Inc. news in 2026
Valion Bio, Inc.'s news releases, calls and decks from 2026, newest first.
Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
October 30, 2026
Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation
October 28, 2026
Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options
October 26, 2026
Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value
October 21, 2026
Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone
October 15, 2026
With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge
October 14, 2026
Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions
September 23, 2026
Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule
September 22, 2026
Valion Bio Announces Reverse Stock Split
August 27, 2026
Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury
August 12, 2026
Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway
July 22, 2026
Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion
July 14, 2026
AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS
June 25, 2026
Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures
June 11, 2026
Valion Bio briefs senior Department of War and BARDA officials in joint engagement on Entolimod for acute radiation syndrome
May 19, 2026
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR Platform
May 15, 2026
Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform
May 14, 2026
Valion Bio reports first quarter 2026 financial results
May 14, 2026
Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026
May 11, 2026
Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™
May 6, 2026
Valion Bio receives first FDA-precedent study protocol from NIAID for Entolimod™; federal agency to fully fund BLA-enabling in vivo program and co-navigate FDA submission
May 5, 2026
Valion Bio Appoints Melinda Lackey as General Counsel
May 4, 2026
Valion Bio briefs Pentagon leadership on Entolimod™ for acute radiation syndrome
April 28, 2026
Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model
April 24, 2026
Calls in 2026
Decks in 2026
- Tivic Health Systems — Investor Presentation (January 2026)
Investor deck · 18 slides · Jan 20, 2026